Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects with Schizophrenia

X
Trial Profile

A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects with Schizophrenia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ulotaront (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 09 Nov 2021 Results of pooled analysis evaluating novelty of a safety profile of a drug in a new class (in clinical trials), against that of those already on the market (using pharmacovigilance data) published in the Clinical Drug Investigation
    • 05 Oct 2021 Results of an analysis assessing effects of SEP-363856 on negative symptoms in initial double-blind study and 6-month open-label extension study presented at the 34th Annual Congress of the European College of Neuropsychopharmacology
    • 05 Oct 2021 Results of pooled analysis assessing the adverse event signals of this first agent in a novel drug class that differentiate it from the available class of atypical antipsychotics, presented at the 34th Annual Congress of the European College of Neuropsychopharmacology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top